Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab is a research paper published in medRxiv (2024). On theSindex it has a DataRank of 0.208. It has been cited 3 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 5R01CA260857-03
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
National Institutes of Health
Grant: 5R01CA260872-03
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
National Institutes of Health
Grant: 5K12CA087723-23
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology
National Institutes of Health
Grant: 1R01CA247441-01A1
Vascularized tumor explants for drug testing
NCI NIH HHS
Grant: K12 CA087723
NCI NIH HHS
Grant: R01 CA247441
NCI NIH HHS
Grant: R01 CA260857
NCI NIH HHS
Grant: R01 CA260872
Fields of Study
Keywords